Press Releases
Search
-
24 Mar 2020
bioMérieux receives Emergency Use Authorization for BIOFIRE® COVID-19 test
bioMérieux, a world leader in the field of in vitro diagnostics, today announced that its subsidiary, BioFire Defense, has received Emergency Use Authorization by the U.S. Food and Drug Administration...
-
11 Mar 2020
First of 3 diagnostic tests for SARS-CoV-2 coronavirus available from bioMérieux
bioMérieux, a world leader in the field of in vitro diagnostics, is announcing the forthcoming launch of 3 different tests to address the COVID-19 epidemic and to meet the different needs of physician...
-
26 Feb 2020
2019 Financial Results
€2,675 million in sales for full-year 2019, representing a reported increase of 10.5% and organic growth of 7.2% Strong sales momentum in the fourth quarter, with organic growth of 8.3% driven by sale...
-
26 Feb 2020
Résultats annuels au 31 décembre 2019
Chiffre d’affaires 2019 de 2 675 millions d’euros, en hausse de 10,5 % à données publiées, soit une croissance organique de 7,2 % Solide dynamique commerciale au 4e trimestre, avec une croissance orga...
-
13 Jan 2020
bioMérieux submits enhanced BIOFIRE® BCID2 Panel for FDA clearance
bioMérieux, a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology affiliate, has submitted to the Food and Drug Administration for 510(k) clear...
-
18 Dec 2019
bioMérieux and the Fleming Fund: working together to strengthen diagnostic capacity and tackle antimicrobial resistance in low- and middle-income countries
London (UK), Marcy l’Étoile (France) – December 18, 2019 – bioMérieux, a world leader in in vitro diagnostics which develops and manufactures testing solutions (systems, reagents, software, services) ...
-
22 Oct 2019
Third-Quarter 2019 Business Review
Organic growth of 6.8% at constant exchange rates and scope of consolidation over the first nine months of the year: €1,928 million in sales Up 10.3% as reported Acceleration of organic growth in sale...
-
04 Sep 2019
First-Half 2019 Results
bioMérieux – First-Half 2019 Results Organic sales growth of 5.5% for first-half 2019: €1,275 million in sales Up 9.1% as reported As expected, growth accelerated in the second quarter, up to 7.4% at ...
-
26 Jun 2019
bioMérieux et l’État de Côte d’Ivoire inaugurent le Centre de formation bioMérieux et signent un accord de collaboration
L’État de Côte d’Ivoire et bioMérieux, acteur mondial du diagnostic in vitro, annoncent la signature d’un mémorandum d’accord de collaboration à l’occasion de l’inauguration du Centre de formation de ...
-
06 Jun 2019
bioMérieux increases its holding in Hybiome from 54% to 67%
bioMérieux, a world leader in the field of in vitro diagnostics, today announced an increase of its shareholding in Suzhou Hybiome Biomedical Engineering Co. Ltd. This announcement follows the earlier...
-
13 May 2019
NEPHROCHECK Biomarkers TIMP-2 and IGFBP7 Included in the ERAS “Guidelines for Perioperative Care in Cardiac Surgery”
The NEPHROCHECK® Test biomarkers (TIMP-2 and IGFBP7) that indicate kidney stress in advance of acute kidney injury (AKI) have been included in the “Guidelines for Perioperative Care in Cardiac Surgery...
-
24 Apr 2019
bioMérieux – First-Quarter 2019 Business Review
Organic growth of 3.8% (at constant exchange rates and scope of consolidation) €632 million in sales Up 7.7% as reported Growth led by the performance in molecular biology, during a first quarter shap...
-
15 Apr 2019
“Global-PPS”, a survey of antibiotic use and bacterial resistance in hospitals worldwide, tops the 200,000 patients
bioMérieux, a world leader in the field of in vitro diagnostics, and the Laboratory of Medical Microbiology at the University of Antwerp announced at ECCMID (European Congress of Clinical Microbiology...
-
02 Apr 2019
University of Antwerp, bioMérieux, and Wellcome Trust to coordinate VALUE-Dx, a European Public-Private Partnership to fight antimicrobial resistance through diagnostics
Antwerp (Belgium), London (UK), Marcy l’Etoile (France) – April 1, 2019 - The University of Antwerp, bioMérieux and Wellcome Trust today announced the launch of VALUE-Dx, the first Innovative Medicine...
-
19 Mar 2019
Baxter et bioMérieux annoncent leur collaboration pour améliorer l'identification et le traitement de l’insuffisance rénale aiguë
Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMérieux, a world leader in the field of in vitro diagnostics, announced an agreement to develop future biomarkers with the g...